Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPI-1620 and docetaxel in advanced biliary cancer
NCT01773785Phase 2Terminated
- Sponsor
- Spectrum Pharmaceuticals, Inc.
- Start
- Apr 2013
- Primary completion
- Sep 2015
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sovateltide in biliary tract cancer (BTC) and gallbladder cancer, sponsored by Spectrum Pharmaceuticals, Inc. Primary endpoint: Progression-Free Survival at 18 months. Started Apr 2013; status: terminated.
02
Drugs
sovateltide
03
Conditions
biliary tract cancer (BTC)gallbladder cancer
Beyond the preview
Go deeper on NCT01773785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01773785.